## Ply Chichareon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4143849/publications.pdf

Version: 2024-02-01

567281 345221 1,376 47 15 36 citations h-index g-index papers 47 47 47 1858 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drugâ€Eluting Stent Implantation: Perâ€Protocol Analysis of the GLOBAL LEADERS Trial. Journal of the American Heart Association, 2022, 11, e024291.	3.7	4
2	Influence of Bleeding Risk on Outcomes of Radial and Femoral Access for Percutaneous Coronary Intervention: An Analysis From the GLOBAL LEADERS Trial. Canadian Journal of Cardiology, 2021, 37, 122-130.	1.7	4
3	Utility of the dual antiplatelet therapy score to guide antiplatelet therapy: A systematic review and metaâ€analysis. Catheterization and Cardiovascular Interventions, 2021, 97, 569-578.	1.7	6
4	Predicting 2â€year all ause mortality after contemporary <scp>PCI</scp> : Updating the logistic clinical <scp>SYNTAX</scp> score. Catheterization and Cardiovascular Interventions, 2021, 98, 1287-1297.	1.7	6
5	Predicting mortality in cardiac care unit patients: external validation of the Mayo cardiac intensive care unit admission risk score. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 1065-1073.	1.0	O
6	The impact of plaque type on strut embedment/protrusion and shear stress distribution in bioresorbable scaffold. European Heart Journal Cardiovascular Imaging, 2020, 21, 454-462.	1.2	5
7	Two years clinical outcomes with the stateâ€ofâ€theâ€art PCI for the treatment of bifurcation lesions: A subâ€analysis of the SYNTAX II study. Catheterization and Cardiovascular Interventions, 2020, 96, 10-17.	1.7	1
8	Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention. JAMA Cardiology, 2020, 5, 21.	6.1	49
9	Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERS. Canadian Journal of Cardiology, 2020, 36, 747-755.	1.7	2
10	Impact of established cardiovascular disease on outcomes in the randomized global leaders trial. Catheterization and Cardiovascular Interventions, 2020, 96, 1369-1378.	1.7	6
11	The influence of implantation techniques on lesion oriented-outcomes in Absorb BVS and Xience EES lesions treated in routine clinical practice at complete three year follow-up: AIDA trial QCA substudy. International Journal of Cardiovascular Imaging, 2020, 36, 565-575.	1.5	O
12	Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial. Clinical Research in Cardiology, 2020, 109, 918-929.	3.3	3
13	Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study. European Heart Journal -Cardiovascular Pharmacotherapy, 2020, 6, 22-30.	3.0	7
14	Prevalence and predictors associated with in-hospital mortality in acute ST segment elevation myocardial infarction after reperfusion therapy in developing country. Cardiovascular Diagnosis and Therapy, 2020, 10, 1264-1269.	1.7	4
15	Advances in IVUS/OCT and Future Clinical Perspective of Novel Hybrid Catheter System in Coronary Imaging. Frontiers in Cardiovascular Medicine, 2020, 7, 119.	2.4	65
16	Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006660.	2.2	11
17	Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, , .	3.0	10
18	Low Body Weight Increases the Risk of Ischemic Stroke and Major Bleeding in Atrial Fibrillation: The COOL-AF Registry. Journal of Clinical Medicine, 2020, 9, 2713.	2.4	6

#	Article	IF	Citations
19	Twilight, the Dawn of a New Era of Aspirin-Free PCI?. Journal of the American College of Cardiology, 2020, 75, 2425-2429.	2.8	6
20	Comparative Assessment of Predictive Performance of PRECISE-DAPT, CRUSADE, and ACUITY Scores in Risk Stratifying 30-Day Bleeding Events. Thrombosis and Haemostasis, 2020, 120, 1087-1095.	3.4	14
21	DAPT Score and the Impact of TicagrelorÂMonotherapy During the Second Year After PCI. JACC: Cardiovascular Interventions, 2020, 13, 634-646.	2.9	17
22	Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. Atherosclerosis, 2020, 295, 45-53.	0.8	36
23	Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. Clinical Research in Cardiology, 2020, 109, 930-943.	3.3	14
24	The impact of pre-procedure heart rate on adverse clinical outcomes in patients undergoing percutaneous coronary intervention: Results from a 2-year follow-up of the GLOBAL LEADERS trial. Atherosclerosis, 2020, 303, 1-7.	0.8	1
25	Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions, 2020, 96, E516-E526.	1.7	5
26	The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial. Clinical Research in Cardiology, 2020, 109, 1125-1139.	3.3	14
27	Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial. EuroIntervention, 2020, 16, 634-644.	3.2	6
28	A comparison of ventricular systolic function indices provided by VolumeView/EV1000â,,¢ and left ventricular ejection fraction by echocardiography among septic shock patients. Journal of Clinical Monitoring and Computing, 2019, 33, 233-239.	1.6	7
29	Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. European Heart Journal, 2019, 40, 2595-2604.	2.2	93
30	Efficacy and Safety of TicagrelorÂMonotherapy in PatientsÂUndergoing Multivessel PCI. Journal of the American College of Cardiology, 2019, 74, 2015-2027.	2.8	23
31	Impact of non-respect of SYNTAX score II recommendation for surgery in patients with left main coronary artery disease treated by percutaneous coronary intervention: an EXCEL substudy. European Journal of Cardio-thoracic Surgery, 2019, 57, 676-683.	1.4	10
32	Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial). American Journal of Cardiology, 2019, 124, 1833-1840.	1.6	5
33	Impact of postâ€procedural minimal stent area on 2â€year clinical outcomes in the SYNTAX II trial. Catheterization and Cardiovascular Interventions, 2019, 93, E225-E234.	1.7	26
34	Mechanical properties and performances of contemporary drug-eluting stent: focus on the metallic backbone. Expert Review of Medical Devices, 2019, 16, 211-228.	2.8	27
35	Serial Optical Coherence Tomography at Baseline, 7 Days, and 1, 3, 6 and 12 Months After Bioresorbable Scaffold Implantation in a Growing Porcine Model. Circulation Journal, 2019, 83, 556-566.	1.6	1
36	Angiography-Derived Fractional Flow Reserve in the SYNTAX II Trial. JACC: Cardiovascular Interventions, 2019, 12, 259-270.	2.9	46

3

#	Article	IF	CITATIONS
37	Contemporary Outcomes Following Coronary Artery Bypass Graft Surgery forÂLeftÂMainÂDisease. Journal of the American College of Cardiology, 2019, 73, 1877-1886.	2.8	33
38	The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial. International Journal of Cardiovascular Imaging, 2019, 35, 1189-1198.	1.5	6
39	Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study. International Journal of Cardiology, 2019, 286, 43-50.	1.7	19
40	Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2019, 74, 2572-2584.	2.8	31
41	Post-implantation shear stress assessment: an emerging tool for differentiation of bioresorbable scaffolds. International Journal of Cardiovascular Imaging, 2019, 35, 409-418.	1.5	10
42	Application of the MADS classification system in a "mega mammoth―stent trial: Feasibility and preliminary clinical implications. Catheterization and Cardiovascular Interventions, 2019, 93, 57-63.	1.7	5
43	Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial. EuroIntervention, 2019, 15, e539-e546.	3.2	16
44	Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial. EuroIntervention, 2019, 15, e1090-e1098.	3.2	16
45	Angiographic late lumen loss revisited: impact on long-term target lesion revascularization. European Heart Journal, 2018, 39, 3381-3389.	2.2	29
46	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet, The, 2018, 392, 940-949.	13.7	555
47	Diagnostic performance of angiography-derived fractional flow reserve: a systematic review and Bayesian meta-analysis. European Heart Journal, 2018, 39, 3314-3321.	2.2	116